Univercells, a Gosselies, Belgium-based a technology company offering novel biomanufacturing platforms, aimed at increasing the availability and affordability of biologics – recombinant proteins and vaccines, closed a €16m ($18.8m) Series B equity financing.
The financing came from Global Health Investment Fund, Korea Investment Partners, The Innovation Fund, Inventures II, and private investors federated by TheClubDeal, a private investment holding. In conjunction with the funding, Rodolphe de Spoelberch, a Belgium-based independent private equity investor joined Univercells as board observer.
The company intends to use the funds to commercialize a diversified portfolio of technology solutions for a variety of vaccines, monoclonal antibodies and enzyme replacement therapies, with the first products available for human use as soon as 2019.
Founded in 2013 by Hugues Bultot, CEO, and José Castillo, CTO, who bring close to 25 years of expertise in the biotechnology and life sciences sectors, Univercells is a technology company offering novel biomanufacturing platforms, aimed at increasing the availability and affordability of biologics – recombinant proteins and vaccines.
The company is concluding technology transfer negotiations with a number of established biologics manufacturers and healthcare providers in China, India and Latin America.
Univercells benefits from support from the Walloon region, and received €3m as early seeding from Takeda in 2015. At the end of 2016, Univercells was awarded a $16m grant from the Bill & Melinda Gates Foundation.